DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

86.06 1.65 −1.88%
Market cap
$33.1B
P/E
33.2×
Fwd P/E
29.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a

DexCom, Inc. (DXCM) Debt to equity

Alert me on Debt to equity

DexCom, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 0.5×, up 0.0× from fiscal 2025 (0.5×). Over the past ten years it has ranged from 0.0× (fiscal 2015) to 1.5× (fiscal 2018); the current reading is higher than 27% of that period. That is above the Medical Devices industry median of 0.1× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2025 0.5× (23.19%)
FY2024 0.6× (50.00%)
FY2023 1.2× 27.32%
FY2022 0.9× (5.77%)
FY2021 1.0× 6.37%
FY2020 0.9× (24.20%)
FY2019 1.2× (20.13%)
FY2018 1.5× 94.99%
FY2017 0.8× 3,601.90%
FY2016 0.0× 102.88%

Quarterly newest first

Period Debt to equity Change
Jun 2026 0.5× 12.88%
Mar 2026 0.4× (7.06%)
Dec 2025 0.5× (0.64%)
Sep 2025 0.5× (5.55%)
42 more quarters

Against its own ten years

Low 0.0× High 1.5×
Ten-year median 0.9×
Current reading's percentile 27

Debt to equity against peers

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on DXCM